Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of 177Lu-trastuzumab endoradiotherapy in relapsed or resistant HER2-positive breast cancer
IRCT20210612051548N3Phase 2Completed
- Sponsor
- Bushehr University of Medical Sciences
- Start
- Jan 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium-177-dota-trastuzumab in breast cancer, sponsored by Bushehr University of Medical Sciences. Primary endpoint: Overall response or disease control proportion. Started Jan 2022; status: completed.
02
Drugs
lutetium-177-dota-trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20210612051548N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210612051548N3.